

Chemotherapy Protocol

DRUG REGIMEN

CAP (Cyclophosphamide, doxorubicin, cisplatin)

Indication for use

Relapsed ovarian cancer with allergy to carboplatin or paclitaxel

Regimen

Doxorubicin 50mg/m² IV bolus
 Cyclophosphamide 500mg/m² IV bolus
 Potassium chloride 20mmol, magnesium chloride 10mmol in 1 litre 0.9% sodium chloride over 2 hours
 Cisplatin 50mg/m² in 500ml 0.9% sodium chloride over 1 hour
 Potassium chloride 20mmol, magnesium chloride 10mmol in 1 litre 0.9% sodium chloride over 2 hours

Every 21 days for 6 cycles

Investigation prior to initiating treatment

U&Es, LFTs, Calcium, phosphate, magnesium, CA125
 MUGA/echo if comorbidities present or if cumulative doxorubicin dose >300mg/m² (lifetime limit for doxorubicin without any other anthracycline exposure 450mg/m²)

Cautions

Renal failure
 Hepatic failure

Investigations and consultations prior to each cycle

U&Es, LFTs, calcium, phosphate, magnesium, CA125
 Review prior to each cycle
 CT scan every 3-4 cycles

Acceptable levels for treatment to proceed (if outside these levels defer one week or contact consultant)

Neutrophils > 1.5; platelets > 100, Hb > 90
 GFR >60ml/min

Side Effects

Myelosuppression, alopecia, nausea & vomiting, hypomagnesaemia, thrombosis, extravasation, stomatitis

Dose Modification Criteria

Haematological toxicity:

Neutrophils	Platelets	Cyclophosphamide and Doxorubicin Doses
≥ 1.5 x 10 ⁹ /L	and ≥ 100 x 10 ⁹ /L	Give 100%
1.0 – 1.4 x 10 ⁹ /L	or 75 – 99 x 10 ⁹ /L	Give 50% dose
< 1.0 x 10 ⁹ /L	or < 75 x 10 ⁹ /L	Delay for 1 week

Renal Impairment:

If severe renal impairment (CrCl <10ml/min) discuss doxorubicin dose with consultant

Cisplatin dose:

CrCl (ml/min)	Cisplatin Dose
> 60	Give 100%
51– 60	Give 75%
40 – 50	Give 50%
< 40	Contraindicated
Dialysis	Give 50%

Cyclophosphamide:

If serum creatinine >120µmol/ml, adjust dose as below:

CrCl (ml/min)	Cyclophosphamide Dose
> 50	Give 100%
10 – 50	Give 75%
< 10	Give 50%

Hepatic impairment:

Cyclophosphamide not recommended if bilirubin >17 or ALT/AST >2-3xULN. Clinical decision

Doxorubicin dose:

Bilirubin (µmol/L)	Doxorubicin Dose
< 20	Give 100%
20 – 50	Give 50%
51 – 85	Give 25%
> 85	Omit
AST/ ALT (units)	Doxorubicin Dose
2 – 3 x normal	Give 75%

Specific Information on Administration

Doxorubicin is a vesicant, administer via a fast-running sodium chloride 0.9% infusion
Ask patient to drink 2 litres over 12 hours after treatment

THIS PROTOCOL HAS BEEN DIRECTED BY DR YIANNAKIS, CLINICIAN FOR OVARIAN CANCER

RESPONSIBILITY FOR THIS PROTOCOL LIES WITH THE HEAD OF SERVICE

DATE March 2017

REVIEW March 2019

VERSION 1